{"id":64058,"date":"2026-04-27T21:09:19","date_gmt":"2026-04-27T13:09:19","guid":{"rendered":"https:\/\/flcube.com\/?p=64058"},"modified":"2026-04-27T21:09:20","modified_gmt":"2026-04-27T13:09:20","slug":"bristol-myers-squibb-and-pfizer-partner-with-mark-cubans-cost-plus-drugs-to-offer-eliquis-at-345-for-30-day-supply-expanding-access-to-blockbuster-anticoagulant","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64058","title":{"rendered":"Bristol-Myers Squibb and Pfizer Partner with Mark Cuban\u2019s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant"},"content":{"rendered":"\n

Bristol-Myers Squibb<\/strong> (NYSE: BMY<\/a>) and Pfizer<\/strong> (NYSE: PFE<\/a>) announced a landmark collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs)<\/strong> to make Eliquis\u00ae (apixaban)<\/strong> available on the direct-to-consumer platform starting 27 April 2026<\/strong>.<\/p>\n\n\n\n

Priced at USD 345 for a 30-day supply<\/strong> with a valid prescription, Eliquis becomes one of the largest branded pharmaceuticals<\/strong> ever offered on the transparency-focused platform, significantly undercutting typical U.S. cash prices that often exceed $500\u2013$600<\/strong> per month.<\/p>\n\n\n\n

Drug Profile & Indications<\/h2>\n\n\n\n
Use Case<\/th>Clinical Indication<\/th><\/tr><\/thead>
1<\/strong><\/td>Reduce risk of stroke and systemic embolism<\/strong> in non-valvular atrial fibrillation (NVAF)<\/td><\/tr>
2<\/strong><\/td>Treat and prevent recurrence<\/strong> of deep vein thrombosis (DVT) and pulmonary embolism (PE)<\/td><\/tr>
3<\/strong><\/td>Prophylaxis<\/strong> of DVT\/PE following hip or knee replacement surgery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Eliquis, a direct oral anticoagulant (DOAC)<\/strong> and Factor Xa inhibitor, generated $14.2 billion in global sales in 2025<\/strong>, making it one of the world\u2019s top-selling medicines. In the U.S., it holds dominant market share among NOACs due to its favorable safety profile and robust outcomes data.<\/p>\n\n\n\n

Strategic Implications of the Partnership<\/h2>\n\n\n\n
Aspect<\/th>Impact<\/th><\/tr><\/thead>
Patient Access<\/strong><\/td>Immediate price relief for uninsured, underinsured, or high-deductible plan patients<\/td><\/tr>
Pricing Transparency<\/strong><\/td>Reinforces industry shift toward consumer-friendly pricing models amid political pressure on drug costs<\/td><\/tr>
Brand Strategy<\/strong><\/td>Proactive defense against biosimilar\/ generic competition (U.S. exclusivity extends to 2026\u20132027<\/strong>)<\/td><\/tr>
Platform Validation<\/strong><\/td>Elevates Cost Plus Drugs as a credible channel for major pharma brands beyond generics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Dynamics<\/h2>\n\n\n\n